

FOR IMMEDIATE RELEASE:

**PROFECTUS BIOSCIENCES TO PRESENT AT
2009 BIO INTERNATIONAL CONVENTION IN ATLANTA**

Baltimore, MD – May 14, 2009 – Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for chronic viral infections, announced today that the company will speak on two industry panels, as well as give a company presentation at the *2009 BIO International Convention*. The conference is taking place in Atlanta, GA from May 18-21, 2009. The company is available to schedule one-on-one partnering meetings through the *BIO Business Forum*. For more information about the conference or to schedule a meeting, please visit <http://convention.bio.org/>.

Company Presentation:

Who: Shawn Patrick O'Brien, Chief Executive Officer of Profectus BioSciences
When: Tuesday, May 19 from 2:20 p.m. - 2:35 p.m.
Where: Room 315, Georgia World Congress Center, 285 Andrew Young International Blvd., NW, Atlanta, Georgia 30313-1591

Panel Presentation One:

Who: Michael A. Egan, Ph.D., Director of Immunology of Profectus BioSciences
Title: "Renewing the Promise of DNA Vaccines: Strategies to Enhance Delivery, Efficacy and Immunogenicity"
Track: Vaccines
When: Wednesday, May 20 at 2:00 p.m. - 3:30 p.m.
Where: Room B309, Georgia World Congress Center

Panel Presentation Two:

Who: Shawn Patrick O'Brien, Chief Executive Officer of Profectus BioSciences
Title: "How to Grow and Retain Your Biotech Dream Team"
Track: Growing the Biotech Workforce
When: Wednesday, May 20 at 4:00 p.m. - 5:30 p.m.
Where: Room B306, Georgia World Congress Center

Shawn Patrick O'Brien, Chief Executive Officer of Profectus BioSciences, commented, "The Company has made significant progress in advancing our vaccine programs in Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV), and we are excited to be entering into the clinic in the Fall. We look forward to discussing our research and company milestones at the *2009 BIO International Convention*, and continue to seek out strategic partnering opportunities."

About Profectus BioSciences Inc.

Profectus BioSciences is an innovative R&D clinical-stage vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Profectus proprietary vaccine design approach combines its plasmid (p) DNA and rVSV (recombinant Vesicular Stomatitis Virus) vectors platforms via a unique prime-boost strategy to enhance an immune response. Profectus has developed a broad pipeline of vaccine products to address Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), Herpes Simplex Virus (HSV) and Malaria. The company's first clinical vaccine candidate for HIV is planned for clinical trials in Q4 of 2009, followed by a therapeutic HCV vaccine.

The Profectus portfolio has secured over \$100M in non-dilutive funding of its programs from multiple sources including National Institutes of Health (NIH) and \$14M in private equity financing, including Cross Atlantic Capital Partners (XACP). Profectus deploys these financial resources in support of its proprietary prime-boost vaccines for multiple indications. In addition, the Company is funding its early research small molecule program for potential partners. For more information, please visit: <http://www.profectusbiosciences.com>.

#

Contact:

Lisa Rivero

LaVoie Group

978-745-4200 x106

lrivero@lavoiegroup.com

<http://www.lavoiegroup.com>